BioStock: Newly appointed CMO sees potential in Stayble Therapeutics

The Gothenburg-based pharmaceutical company Stayble Therapeutics recently announced Jarkko Kalliomäki as Chief Medical Officer of the company. He is an experienced pain physician and will contribute valuable expertise to the clinical development of the STA363 injection treatment, as well as in future partnership discussions. BioStock interviewed Jarkko Kalliomäki about his new role.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/04/newly-appointed-cmo-sees-potential-in-stayble-therapeutics/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se